The symposia and peer-to-peer “clinicalXchange” presentations hosted by Orion at the 39th ISICEM International Symposium on Intensive Care and Emergency Medicine, 2019, Brussels had a strong focus on levosimendan and what makes it unique as a first-line inotrope. Find out why this is a kidney friendly inodilator and how to optimise treatment in CABG. You can also learn why decatecholimization is the way forward in the ICU. Watch the videos to see the practical aspects, limitations and pitfalls of levosimendan in cardiac surgery and how new analysis are shedding more light on its use in different operative scenarios.
Watch the videos below for further insights.
Prof. Dr Heringlake explores the need for new therapeutic concepts in high risk CABG patients and the positive effects of preoperative levosimendan in reducing mortality in patients undergoing isolated CABG.
What is known about levosimendan and the kidney? Watch Professor Ricksten as he reviews this question and points out the difference between levosimendan compared to other inotropes.
What makes levosimendan different from other inotropes? Discover the use of levosimendan in different settings, while Dr Herpain explores the benefits of this agent, especially on cardio-renal function.
Are catecholamines safe in critically ill patients? Find out about their negative effects and why it’s time to consider better alternatives.
Prof. Dr Heringlake gives a concise overview of the rationale behind using levosimendan as a first-line agent and runs through the literature suggesting its optimum use. Find out why this drug is not only good for the heart but also good for the kidney.